Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild and Moderate Hepatic Impairment Clear all
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

NCT01762462
View directory record Official record
Conditions
Hepatic Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on LDE225..

NCT01764776
View directory record Official record
Conditions
Normal Hepatic Function, Impaired Hepatic Function
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536911
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
LY3502970
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

NCT05599932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Siremadlin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464
View directory record Official record
Conditions
Hepatic Cirrhosis, Alcoholism
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT01571388
View directory record Official record
Conditions
Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions
dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

NCT05935033
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01456663
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

NCT03814005
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

NCT04482270
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
fezolinetant
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Clearwater, Florida • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

NCT01863784
View directory record Official record
Conditions
Hepatic Impairment
Interventions
JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Orlando, Florida • Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347
View directory record Official record
Conditions
Liver Diseases
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

NCT05560464
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • Orlando, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

NCT05517226
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Cotadutide
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Hialeah, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Research Study on Etavopivat in Participants With and Without Liver Disease

NCT06336018
View directory record Official record
Conditions
Liver Diseases
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

NCT01126086
View directory record Official record
Conditions
Hepatic Impairment
Interventions
otamixaban XRP0673
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami Gardens, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227
View directory record Official record
Conditions
Liver Disease, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911
View directory record Official record
Conditions
Hepatic Impairment
Interventions
S-217622
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of AGO178 in Participants With Liver Impairment

NCT01531309
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

NCT07018492
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pretomanid in Adults With Hepatic Impairment

NCT02422524
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

NCT06004934
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634
View directory record Official record
Conditions
Hepatic Impairment
Interventions
envudeucitinib
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Lake Forest, California • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 4:05 PM EDT